Hardip Sandhu
Research Subjects
Hardip Sandhu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Helen L. Maddock
Institute for Cardiometabolic Medicine, University Hospitals Coventry & Warwickshire NHS Trust (V.A., V.G.L., S.M.Z.R., H.S., M.S.D., D.R., H.M., F.O.).
4 shared publications Helen Maddock
Coventry University
3 shared publications- Lars Edvinsson
Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University, Lund, Sweden
3 shared publications - Samantha Louise Cooper
Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK
3 shared publications - Afthab Hussain
Centre for Sport, Exercise and Life Sciences, Alison Gingell Building, Faculty of Health and Life Sciences, Coventry University, CV1 2DS, United Kingdom
2 shared publications - Cang-Bao Xu
Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Cardiac Electrophysiological Impact of Sodium Glucose Cotransporter 2 Inhibitors: A Comprehensive Review
SGLT2i (sodium-glucose cotransporter 2 inhibitors) reduce heart failure hospitalizations, cardiovascular death, and certain arrhythmic events beyond glycemic control. However, their specific effects on cardiac autonomic function and arrhythmogenesis, as well as the potential involvement of miRNAs (microRNAs) in mediating these benefits, remain incompletely understood. This review synthesizes clinical and preclinical evidence on the impact of SGLT2i on cardiac autonomic regulation and arrhythmias, emphasizing the interplay between SGLT2i, miRNA expression, and cardiovascular risk. We conducted a comprehensive literature search for clinical trials, meta-analyses, observational studies, and preclinical investigations. Outcomes included heart rate variability, heart rate turbulence, atrial/ventricular arrhythmias, and sudden cardiac death. Studies examining miRNA profiles associated with SGLT2i treatment and their links to cardiac fibrosis, inflammation, and arrhythmogenic substrates were analyzed in depth. Clinical evidence indicates that SGLT2i improve cardiac autonomic balance by reducing sympathetic overactivity and enhancing parasympathetic tone in patients with type 2 diabetes and cardiac autonomic neuropathy. Meta-analyses and post hoc data from cardiovascular outcome trials suggest a modest but consistent reduction in atrial fibrillation/flutter and, in some cohorts, sudden cardiac death, potentially reflecting sympathoinhibition, improved hemodynamics, and modulation of myocardial ion homeostasis. Preclinical studies support anti-arrhythmic properties through sodium-hydrogen exchanger inhibition, late sodium current suppression, and metabolic shift towards ketone utilization. SGLT2i modulate several key miRNAs implicated in heart failure and arrhythmic risk, including miR-21, miR-29, miR-30, miR-34a, and miR-92, which may partly underlie the attenuation of arrhythmogenic substrates and improved autonomic regulation. SGLT2i favorably affect cardiac autonomic function and reduce the burden of certain arrhythmias, potentially through modulation of disease-associated miRNAs. Integrating clinical autonomic outcomes with miRNA profiling provides mechanistic insights into their cardioprotective actions. Dedicated trials are warranted to clarify causality, dose-dependency, and the therapeutic potential of miRNA-SGLT2i interactions for arrhythmia prevention and management in high-risk populations.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Cardiac Electrophysiological Impact of Sodium Glucose Cotransporter 2 Inhibitors: A Comprehensive Review
SGLT2i (sodium-glucose cotransporter 2 inhibitors) reduce heart failure hospitalizations, cardiovascular death, and certain arrhythmic events beyond glycemic control. However, their specific effects on cardiac autonomic function and arrhythmogenesis, as well as the potential involvement of miRNAs (microRNAs) in mediating these benefits, remain incompletely understood. This review synthesizes clinical and preclinical evidence on the impact of SGLT2i on cardiac autonomic regulation and arrhythmias, emphasizing the interplay between SGLT2i, miRNA expression, and cardiovascular risk. We conducted a comprehensive literature search for clinical trials, meta-analyses, observational studies, and preclinical investigations. Outcomes included heart rate variability, heart rate turbulence, atrial/ventricular arrhythmias, and sudden cardiac death. Studies examining miRNA profiles associated with SGLT2i treatment and their links to cardiac fibrosis, inflammation, and arrhythmogenic substrates were analyzed in depth. Clinical evidence indicates that SGLT2i improve cardiac autonomic balance by reducing sympathetic overactivity and enhancing parasympathetic tone in patients with type 2 diabetes and cardiac autonomic neuropathy. Meta-analyses and post hoc data from cardiovascular outcome trials suggest a modest but consistent reduction in atrial fibrillation/flutter and, in some cohorts, sudden cardiac death, potentially reflecting sympathoinhibition, improved hemodynamics, and modulation of myocardial ion homeostasis. Preclinical studies support anti-arrhythmic properties through sodium-hydrogen exchanger inhibition, late sodium current suppression, and metabolic shift towards ketone utilization. SGLT2i modulate several key miRNAs implicated in heart failure and arrhythmic risk, including miR-21, miR-29, miR-30, miR-34a, and miR-92, which may partly underlie the attenuation of arrhythmogenic substrates and improved autonomic regulation. SGLT2i favorably affect cardiac autonomic function and reduce the burden of certain arrhythmias, potentially through modulation of disease-associated miRNAs. Integrating clinical autonomic outcomes with miRNA profiling provides mechanistic insights into their cardioprotective actions. Dedicated trials are warranted to clarify causality, dose-dependency, and the therapeutic potential of miRNA-SGLT2i interactions for arrhythmia prevention and management in high-risk populations.
- 16 September 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1006, 178162
Doxorubicin increases G-protein coupled receptor-mediated vasoconstriction in coronary arteries via the mitogen-activated protein kinase kinase 1/2 pathway
- 16 September 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1006, 178162
Doxorubicin increases G-protein coupled receptor-mediated vasoconstriction in coronary arteries via the mitogen-activated protein kinase kinase 1/2 pathway
- 8 February 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (8) , 5831-5845
Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries
Doxorubicin (Doxo)-associated cardio-and vasotoxicity has been recognised as a serious complication of cancer chemotherapy. The purpose of this novel paper was to determine the effect of Doxo on G-protein coupled receptor (GPCR)-mediated vasocontraction located on vascular smooth muscle cells. Rat left anterior descending artery segments were incubated for 24 h with 0.5 µM Doxo. The vasocontractile responses by activation of endothelin receptor type A (ETA) and type B (ETB), serotonin receptor 1B (5-HT1B) and thromboxane A2 prostanoid receptor (TP) were investigated by a sensitive myography using specific agonists, while the specificity of the GPCR agonists was verified by applying selective antagonists (i.e. ETA and ETB agonist = 10- 14-10- 7.5 M endothelin-1 (ET-1); ETA antagonist = 10 µM BQ123; ETB agonists = 10- 14-10- 7.5 M sarafotoxin 6c (S6c) and ET-1; ETB antagonist = 0.1 µM BQ788; 5-HT1B agonist = 10- 12-10- 5.5 M 5-carboxamidotryptamine (5-CT); 5-HT1B antagonist = 1 µM GR55562; TP agonist = 10- 12-10- 6.5 M U46619; TP antagonist = 1 µM Seratrodast). Our results show that 0.5 µM Doxo incubation of LAD segments leads to an increased VSMC vasocontraction through the ETB, 5-HT1B and TP GPCRs, with a 2.2-fold increase in ETB-mediated vasocontraction at 10- 10.5 M S6c, a 2.0-fold increase in 5-HT1B-mediated vasocontraction at 10- 5.5 M 5-CT, and a 1.3-fold increase in TP-mediated vasocontraction at 10- 6.5 M U46619. Further studies unravelling the involvement of intracellular GPCR signalling pathways will broaden our understanding of the Doxo-induced vasotoxicity, and thus pave the way to mitigate the adverse effects by potential implementation of adjunct therapy options.
- 8 February 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (8) , 5831-5845
Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries
Doxorubicin (Doxo)-associated cardio-and vasotoxicity has been recognised as a serious complication of cancer chemotherapy. The purpose of this novel paper was to determine the effect of Doxo on G-protein coupled receptor (GPCR)-mediated vasocontraction located on vascular smooth muscle cells. Rat left anterior descending artery segments were incubated for 24 h with 0.5 µM Doxo. The vasocontractile responses by activation of endothelin receptor type A (ETA) and type B (ETB), serotonin receptor 1B (5-HT1B) and thromboxane A2 prostanoid receptor (TP) were investigated by a sensitive myography using specific agonists, while the specificity of the GPCR agonists was verified by applying selective antagonists (i.e. ETA and ETB agonist = 10- 14-10- 7.5 M endothelin-1 (ET-1); ETA antagonist = 10 µM BQ123; ETB agonists = 10- 14-10- 7.5 M sarafotoxin 6c (S6c) and ET-1; ETB antagonist = 0.1 µM BQ788; 5-HT1B agonist = 10- 12-10- 5.5 M 5-carboxamidotryptamine (5-CT); 5-HT1B antagonist = 1 µM GR55562; TP agonist = 10- 12-10- 6.5 M U46619; TP antagonist = 1 µM Seratrodast). Our results show that 0.5 µM Doxo incubation of LAD segments leads to an increased VSMC vasocontraction through the ETB, 5-HT1B and TP GPCRs, with a 2.2-fold increase in ETB-mediated vasocontraction at 10- 10.5 M S6c, a 2.0-fold increase in 5-HT1B-mediated vasocontraction at 10- 5.5 M 5-CT, and a 1.3-fold increase in TP-mediated vasocontraction at 10- 6.5 M U46619. Further studies unravelling the involvement of intracellular GPCR signalling pathways will broaden our understanding of the Doxo-induced vasotoxicity, and thus pave the way to mitigate the adverse effects by potential implementation of adjunct therapy options.
- Open Access
- 7 December 2023
- Published by Springer Nature in Research Square
Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries
Doxorubicin (Doxo)-associated cardio-and vasotoxicity has been recognised as a serious complication of cancer chemotherapy. The purpose of this novel paper was to determine the effect of Doxo on G-protein coupled receptor (GPCR)-mediated vasocontraction located on vascular smooth muscle cells. Rat left anterior descending artery segments were incubated for 24 h with 0.5 µM Doxo was applied. The vasocontractile responses by activation of endothelin receptor type A (ETA) and type B (ETB), serotonin receptor 1B (5-HT1B) and thromboxane A2 prostanoid receptor (TP) were investigated by a sensitive myography using specific agonists, while the specificity of the GPCR agonists was verified by applying selective antagonists (i.e. ETA agonist = 10-14-10-7.5 M endothelin-1 (ET-1); ETA antagonist = 10 µM BQ123; ETB agonists = 10-14-10-7.5 M sarafotoxin 6c (S6c) and ET-1; ETB antagonist = 0.1 µM BQ788; 5-HT1B agonist = 10-12-10-5.5 M 5-carboxamidotryptamine (5-CT); 5-HT1B antagonist = 1 µM GR55562; TP agonist = 10-12-10-6.5 M U46619; TP antagonist = 1 µM Seratrodast). Our results show that 0.5 µM Doxo incubation of LAD segments leads to an increased VSMC vasocontraction through the ETB, 5-HT1B and TP GPCRs, with a 2.2-fold increase in ETB-mediated vasocontraction at 10-10.5 M S6c, a 2.0-fold increase in 5-HT1B-mediated vasocontraction at 10-5.5 M 5-CT, and a 1.3-fold increase in TP-mediated vasocontraction at 10-6.5 M U46619. Further studies unravelling the involvement of intracellular GPCR signalling pathways will broaden our understanding of the Doxo-induced vasotoxicity, and thus pave the way to mitigate the adverse effects by potential implementation of adjunct therapy options.
- 7 December 2023
- Published by Springer Nature in Research Square
Open AccessDoxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries
Doxorubicin (Doxo)-associated cardio-and vasotoxicity has been recognised as a serious complication of cancer chemotherapy. The purpose of this novel paper was to determine the effect of Doxo on G-protein coupled receptor (GPCR)-mediated vasocontraction located on vascular smooth muscle cells. Rat left anterior descending artery segments were incubated for 24 h with 0.5 µM Doxo was applied. The vasocontractile responses by activation of endothelin receptor type A (ETA) and type B (ETB), serotonin receptor 1B (5-HT1B) and thromboxane A2 prostanoid receptor (TP) were investigated by a sensitive myography using specific agonists, while the specificity of the GPCR agonists was verified by applying selective antagonists (i.e. ETA agonist = 10-14-10-7.5 M endothelin-1 (ET-1); ETA antagonist = 10 µM BQ123; ETB agonists = 10-14-10-7.5 M sarafotoxin 6c (S6c) and ET-1; ETB antagonist = 0.1 µM BQ788; 5-HT1B agonist = 10-12-10-5.5 M 5-carboxamidotryptamine (5-CT); 5-HT1B antagonist = 1 µM GR55562; TP agonist = 10-12-10-6.5 M U46619; TP antagonist = 1 µM Seratrodast). Our results show that 0.5 µM Doxo incubation of LAD segments leads to an increased VSMC vasocontraction through the ETB, 5-HT1B and TP GPCRs, with a 2.2-fold increase in ETB-mediated vasocontraction at 10-10.5 M S6c, a 2.0-fold increase in 5-HT1B-mediated vasocontraction at 10-5.5 M 5-CT, and a 1.3-fold increase in TP-mediated vasocontraction at 10-6.5 M U46619. Further studies unravelling the involvement of intracellular GPCR signalling pathways will broaden our understanding of the Doxo-induced vasotoxicity, and thus pave the way to mitigate the adverse effects by potential implementation of adjunct therapy options.
- 1 June 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (6) , 799-807
Metformin Protects Against Sunitinib-induced Cardiotoxicity: Investigating the Role of AMPK
Sunitinib is associated with cardiotoxicity through inhibition of AMP-protein kinase (AMPK) signaling. By contrast, the common antidiabetic agent metformin has demonstrated cardioprotection through indirect AMPK activation. In this study, we investigate the effects of metformin during sunitinib-induced cytotoxicity. Left ventricular developed pressure, coronary flow, heart rate, and infarct size were measured in Langendorff-perfused rat hearts treated with 1 µM sunitinib ±50 µM metformin ±1 µM human equilibrative nucleoside transporter inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI). Western blot analysis was performed for p-AMPKα levels. Primary isolated cardiac myocytes from the left ventricular tissue were used to measure live cell population levels. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess adjunctive treatment of and metformin in human hepatoma G2 and promyelocytic leukemia (HL-60) cells treated with 0.1–100 µM sunitinib ±50 µM metformin. In the perfused hearts, coadministration of metformin attenuated the sunitinib-induced changes to left ventricular developed pressure, infarct size, and cardiac myocyte population. Western blot analysis revealed a significant decrease in p-AMPKα during sunitinib treatment, which was attenuated after coadministration with metformin. All metformin-induced effects were attenuated, and NBTI was coadministered. The MTT assay demonstrated an increase in the EC50 value during coadministration of metformin with sunitinib compared with sunitinib monotherapy in hepatoma G2 and HL-60 cell lines, demonstrating the impact and complexity of metformin coadministration and the possible role of AMPK signaling. This study highlights the novel cardioprotective properties of metformin and AMPK activation during sunitinib-induced cardiotoxicity when administered together in the Langendorff heart model.
- 1 June 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (6) , 799-807
Metformin Protects Against Sunitinib-induced Cardiotoxicity: Investigating the Role of AMPK
Sunitinib is associated with cardiotoxicity through inhibition of AMP-protein kinase (AMPK) signaling. By contrast, the common antidiabetic agent metformin has demonstrated cardioprotection through indirect AMPK activation. In this study, we investigate the effects of metformin during sunitinib-induced cytotoxicity. Left ventricular developed pressure, coronary flow, heart rate, and infarct size were measured in Langendorff-perfused rat hearts treated with 1 µM sunitinib ±50 µM metformin ±1 µM human equilibrative nucleoside transporter inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI). Western blot analysis was performed for p-AMPKα levels. Primary isolated cardiac myocytes from the left ventricular tissue were used to measure live cell population levels. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess adjunctive treatment of and metformin in human hepatoma G2 and promyelocytic leukemia (HL-60) cells treated with 0.1–100 µM sunitinib ±50 µM metformin. In the perfused hearts, coadministration of metformin attenuated the sunitinib-induced changes to left ventricular developed pressure, infarct size, and cardiac myocyte population. Western blot analysis revealed a significant decrease in p-AMPKα during sunitinib treatment, which was attenuated after coadministration with metformin. All metformin-induced effects were attenuated, and NBTI was coadministered. The MTT assay demonstrated an increase in the EC50 value during coadministration of metformin with sunitinib compared with sunitinib monotherapy in hepatoma G2 and HL-60 cell lines, demonstrating the impact and complexity of metformin coadministration and the possible role of AMPK signaling. This study highlights the novel cardioprotective properties of metformin and AMPK activation during sunitinib-induced cardiotoxicity when administered together in the Langendorff heart model.
- Open Access
- 23 April 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 634291
Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19
Anti-cancer treatment regimens can lead to both acute- and long-term myocardial injury due to off-target effects. Besides, cancer patients and survivors are severely immunocompromised due to the harsh effect of anti-cancer therapy targeting the bone marrow cells. Cancer patients and survivors can therefore be potentially extremely clinically vulnerable and at risk from infectious diseases. The recent global outbreak of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its infection called coronavirus disease 2019 (COVID-19) has rapidly become a worldwide health emergency, and on March 11, 2020, COVID-19 was declared a global pandemic by the World Health Organization (WHO). A high fatality rate has been reported in COVID-19 patients suffering from underlying cardiovascular diseases. This highlights the critical and crucial aspect of monitoring cancer patients and survivors for potential cardiovascular complications during this unprecedented health crisis involving the progressive worldwide spread of COVID-19. COVID-19 is primarily a respiratory disease; however, COVID-19 has shown cardiac injury symptoms similar to the cardiotoxicity associated with anti-cancer therapy, including arrhythmia, myocardial injury and infarction, and heart failure. Due to the significant prevalence of micro- and macro-emboli and damaged vessels, clinicians worldwide have begun to consider whether COVID-19 may in fact be as much a vascular disease as a respiratory disease. However, the underlying mechanisms and pathways facilitating the COVID-19-induced cardiac injury in cancer and non-cancer patients remain unclear. Investigations into whether COVID-19 cardiac injury and anti-cancer drug-induced cardiac injury in cancer patients and survivors might synergistically increase the cardiovascular complications and comorbidity risk through a “two-hit” model are needed. Identification of cardiac injury mechanisms and pathways associated with COVID-19 development overlapping with anti-cancer therapy could help clinicians to allow a more optimized prognosis and treatment of cancer survivors suffering from COVID-19. The following review will focus on summarizing the harmful cardiovascular risk of COVID-19 in cancer patients and survivors treated with an anti-cancer drug. This review will improve the knowledge of COVID-19 impact in the field of cardio-oncology and potentially improve the outcome of patients.
- 23 April 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 634291
Open AccessAnti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19
Anti-cancer treatment regimens can lead to both acute- and long-term myocardial injury due to off-target effects. Besides, cancer patients and survivors are severely immunocompromised due to the harsh effect of anti-cancer therapy targeting the bone marrow cells. Cancer patients and survivors can therefore be potentially extremely clinically vulnerable and at risk from infectious diseases. The recent global outbreak of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its infection called coronavirus disease 2019 (COVID-19) has rapidly become a worldwide health emergency, and on March 11, 2020, COVID-19 was declared a global pandemic by the World Health Organization (WHO). A high fatality rate has been reported in COVID-19 patients suffering from underlying cardiovascular diseases. This highlights the critical and crucial aspect of monitoring cancer patients and survivors for potential cardiovascular complications during this unprecedented health crisis involving the progressive worldwide spread of COVID-19. COVID-19 is primarily a respiratory disease; however, COVID-19 has shown cardiac injury symptoms similar to the cardiotoxicity associated with anti-cancer therapy, including arrhythmia, myocardial injury and infarction, and heart failure. Due to the significant prevalence of micro- and macro-emboli and damaged vessels, clinicians worldwide have begun to consider whether COVID-19 may in fact be as much a vascular disease as a respiratory disease. However, the underlying mechanisms and pathways facilitating the COVID-19-induced cardiac injury in cancer and non-cancer patients remain unclear. Investigations into whether COVID-19 cardiac injury and anti-cancer drug-induced cardiac injury in cancer patients and survivors might synergistically increase the cardiovascular complications and comorbidity risk through a “two-hit” model are needed. Identification of cardiac injury mechanisms and pathways associated with COVID-19 development overlapping with anti-cancer therapy could help clinicians to allow a more optimized prognosis and treatment of cancer survivors suffering from COVID-19. The following review will focus on summarizing the harmful cardiovascular risk of COVID-19 in cancer patients and survivors treated with an anti-cancer drug. This review will improve the knowledge of COVID-19 impact in the field of cardio-oncology and potentially improve the outcome of patients.
- 1 January 2019
- Published by Elsevier in Toxicology
- Vol. 411, 49-59
Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association
- 1 January 2019
- Published by Elsevier in Toxicology
- Vol. 411, 49-59
Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association
- 1 February 2018
- Published by Elsevier in Toxicology
- Vol. 394, 72-83
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity
- 1 February 2018
- Published by Elsevier in Toxicology
- Vol. 394, 72-83
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity
- 1 November 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 814, 95-105
Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation
- 1 November 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 814, 95-105
Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation